Acurian Delivers Thousands of Patients and Accelerates Enrollment Timelines for a Global Multi-Protocol Lipid Lowering Program

Cardiovasular

Hyperlipidemia/High Triglycerides

A sponsor’s injectable lipid lowering drug was in a first-to-market race against two competitors when it launched an eight-protocol, phase III global program. Six protocols were evaluating the LDL-C lowering efficacy, safety, and tolerability of the drug, and two studies were investigating its ability to reduce major cardiovascular events.

Read More »